Inhibition_NN
of_IN
lipopolysaccharide-induced_JJ
monocyte_NN
interleukin-1_NN
receptor_NN
antagonist_NN
synthesis_NN
by_IN
cortisol_NN
:_:
involvement_NN
of_IN
the_DT
mineralocorticoid_NN
receptor_NN
._.

Glucocorticoids_NNS
,_,
as_IN
a_DT
part_NN
of_IN
their_PRP$
physiological_JJ
role_NN
in_IN
the_DT
control_NN
of_IN
inflammatory_JJ
and_CC
immune_JJ
processes_NNS
,_,
suppress_VBP
the_DT
expression_NN
of_IN
interleukin-1_NN
-LRB-_-LRB-
IL-1_NN
-RRB-_-RRB-
and_CC
other_JJ
cytokines_NNS
._.

Human_JJ
monocyte_NN
IL-1_NN
receptor_NN
antagonist_NN
-LRB-_-LRB-
IL-1ra_NN
-RRB-_-RRB-
messenger_NN
ribonucleic_NN
acid_NN
-LRB-_-LRB-
mRNA_NN
-RRB-_-RRB-
expression_NN
and_CC
protein_NN
secretion_NN
are_VBP
inhibited_VBN
by_IN
dexamethasone_NN
._.

We_PRP
have_VBP
now_RB
further_RB
studied_VBN
the_DT
regulation_NN
of_IN
IL-1ra_NN
by_IN
the_DT
major_JJ
physiological_JJ
human_JJ
glucocorticoid_NN
,_,
cortisol_NN
._.

We_PRP
found_VBD
that_IN
cortisol_NN
incubation_NN
induced_VBD
a_DT
decrease_NN
in_IN
IL-1ra_NN
mRNA_NN
expression_NN
and_CC
a_DT
significant_JJ
inhibition_NN
of_IN
IL-1ra_NN
protein_NN
secretion_NN
in_IN
cell_NN
cultures_NNS
of_IN
human_JJ
peripheral_JJ
monocytes_NNS
stimulated_VBN
with_IN
the_DT
bacterial_JJ
endotoxin_NN
lipopolysaccharide_NN
-LRB-_-LRB-
LPS_NN
-RRB-_-RRB-
._.

Oral_JJ
administration_NN
of_IN
276_CD
mumol_NN
cortisol_NN
to_TO
normal_JJ
subjects_NNS
also_RB
decreased_VBD
LPS-induced_JJ
IL-1ra_NN
synthesis_NN
in_IN
cultured_VBN
monocytes_NNS
._.

By_IN
coincubating_VBG
the_DT
monocytes_NNS
with_IN
either_CC
the_DT
mineralocorticoid_NN
antagonist_NN
spironolactone_NN
or_CC
the_DT
glucocorticoid_NN
receptor_NN
antagonist_NN
RU_NN
38486_CD
,_,
the_DT
in_FW
vitro_FW
cortisol-induced_JJ
inhibition_NN
of_IN
LPS-stimulated_JJ
IL-1ra_NN
secretion_NN
was_VBD
partially_RB
reversed_VBN
._.

The_DT
mineralocorticoid_NN
aldosterone_NN
exerted_VBD
a_DT
significant_JJ
decrease_NN
in_IN
LPS-induced_JJ
monocyte_NN
IL-1ra_NN
secretion_NN
in_FW
vitro_FW
,_,
which_WDT
was_VBD
blocked_VBN
by_IN
coincubation_NN
with_IN
spironolactone_NN
._.

In_IN
addition_NN
,_,
the_DT
expression_NN
of_IN
mineralocorticoid_NN
receptor_NN
mRNA_NN
in_IN
human_JJ
monocytes_NNS
was_VBD
observed_VBN
by_IN
PCR_NN
of_IN
reversed_VBN
transcribed_VBN
RNA_NN
._.

Our_PRP$
results_NNS
further_RB
indicate_VBP
that_IN
corticosteroids_NNS
physiologically_RB
control_VBP
the_DT
IL-1_NN
\/_:
IL-1ra_NN
system_NN
during_IN
inflammatory_JJ
or_CC
immune_JJ
processes_NNS
._.

Moreover_RB
,_,
we_PRP
provide_VBP
evidence_NN
that_IN
,_,
in_IN
addition_NN
to_TO
a_DT
glucocorticoid_NN
receptor-mediated_JJ
effect_NN
,_,
the_DT
mineralocorticoid_NN
receptor_NN
is_VBZ
involved_VBN
in_IN
the_DT
inhibition_NN
of_IN
monocyte_NN
IL-1ra_NN
secretion_NN
by_IN
cortisol_NN
._.

